Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H15NO |
| Molecular Weight | 165.2322 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@@H](C)[C@H](O)C1=CC=CC=C1
InChI
InChIKey=KWGRBVOPPLSCSI-WPRPVWTQSA-N
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1
| Molecular Formula | C10H15NO |
| Molecular Weight | 165.2322 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Ephedrine (l-form) is an alkaloid, which was initially purified from Ephedra plant. The extract form Ephedra has been used in China for medicinal purposes for several thousand years. Ephedrine acts as an agonist at alpha- and beta-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. The drug crosses the blood brain barrier and stimulates the central nervous system. Ephedrine products are now banned in many countries, as they are a major source for the production of the addictive compound methamphetamine. FDA has approved ephedrine only for the treatment of clinically important hypotension occurring in the setting of anesthesia.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P07550|||Q53GA6|||Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) |
0.36 µM [EC50] | ||
Target ID: CHEMBL2094251 |
4.95 null [pKi] | ||
Target ID: P08588 Gene ID: 153.0 Gene Symbol: ADRB1 Target Organism: Homo sapiens (Human) |
0.5 µM [EC50] | ||
Target ID: CHEMBL2095158 |
4.83 null [pKi] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | AKOVAZ Approved UseAKOVAZ injection is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. Launch Date2016 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
79.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/ |
22 mg single, oral dose: 22 mg route of administration: Oral experiment type: SINGLE co-administered: |
EPHEDRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
87.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/ |
11 mg 3 times / day multiple, oral dose: 11 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EPHEDRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.75 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/ |
22 mg single, oral dose: 22 mg route of administration: Oral experiment type: SINGLE co-administered: |
EPHEDRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/ |
11 mg 3 times / day multiple, oral dose: 11 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EPHEDRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacologic options available to treat symptomatic intradialytic hypotension. | 2001-10 |
|
| The anesthetic management of triplet cesarean delivery: a retrospective case series of maternal outcomes. | 2001-10 |
|
| High performance liquid chromatography with UV detection for the simultaneous determination of sympathomimetic amines using 4-(4,5-diphenyl-1H-imidazole-2-yl)benzoyl chloride as a label. | 2001-10 |
|
| [Risk management by reporting critical incidents. Vitamin K and ephedrine mix-up at a birthing unit]. | 2001-09-24 |
|
| Rapid chiral on-chip separation with simplified amperometric detection. | 2001-09-14 |
|
| Effect of sympathetic reinnervation on cardiac performance after heart transplantation. | 2001-09-06 |
|
| Simultaneous quantitation of ephedrines in urine by gas chromatography-nitrogen-phosphorus detection for doping control purposes. | 2001-09-05 |
|
| Time-controlled release pseudoephedrine tablets: bioavailability and in vitro/in vivo correlations. | 2001-09 |
|
| Phenylephrine added to prophylactic ephedrine infusion during spinal anesthesia for elective cesarean section. | 2001-09 |
|
| Separation and determination of ephedrine alkaloids and tetramethylpyrazine in Ephedra sinica Stapf by gas chromatography-mass spectrometry. | 2001-09 |
|
| What constitutes an effective but safe initial dose of lidocaine to test a thoracic epidural catheter? | 2001-09 |
|
| Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. | 2001-09 |
|
| Studying the neuronal side of the synaptic cleft. A tool for investigating the paradox of sympathetic nervous system and heart failure in dilated cardiomyopathy. | 2001-09 |
|
| Kinetic spectrophotometric methods for the quantitation of triprolidine in bulk and in drug formulations. | 2001-09 |
|
| Use of nonprescription weight loss products: results from a multistate survey. | 2001-08-31 |
|
| The trouble with fat-burner pills. | 2001-08-27 |
|
| Continuous production of (R)-phenylacetylcarbinol in an enzyme-membrane reactor using a potent mutant of pyruvate decarboxylase from Zymomonas mobilis. | 2001-08-20 |
|
| Application of carboxymethyl-beta-cyclodextrin as a chiral selector in capillary electrophoresis for enantiomer separation of selected neurotransmitters. | 2001-08-17 |
|
| Asymmetric synthesis of chiral organofluorine compounds: use of nonracemic fluoroiodoacetic acid as a practical electrophile and its application to the synthesis of monofluoro hydroxyethylene dipeptide isosteres within a novel series of HIV protease inhibitors. | 2001-08-01 |
|
| Intrathecal anaesthesia for the elderly patient: the influence of the induction position on perioperative haemodynamic stability and patient comfort. | 2001-08 |
|
| Role of the atrial natriuretic factor in obstetric spinal hypotension. | 2001-08 |
|
| Comparison of metaraminol and ephedrine infusions for maintaining arterial pressure during spinal anesthesia for elective cesarean section. | 2001-08 |
|
| Dose of prophylactic intravenous ephedrine during spinal anesthesia for cesarean section. | 2001-08 |
|
| Prevention and management of hypotension during spinal anaesthesia for elective Caesarean section: a survey of practice. | 2001-08 |
|
| Hypokalemic metabolic acidosis attributed to cough mixture abuse. | 2001-08 |
|
| Effect of caffeine and ephedrine ingestion on anaerobic exercise performance. | 2001-08 |
|
| Determination of ephedrines in urine by gas chromatography-mass spectrometry. | 2001-07-15 |
|
| The effect of betahistine on vestibular habituation: comparison of rotatory and sway habituation training. | 2001-07 |
|
| Pre-filled ephedrine syringes. | 2001-07 |
|
| The olfactory G protein G(alphaolf) possesses a lower GDP-affinity and deactivates more rapidly than G(salphashort): consequences for receptor-coupling and adenylyl cyclase activation. | 2001-07 |
|
| A stable gas chromatography-mass spectrometry analysis system to characterize Ma Huang products found in health foods and supplements. | 2001-07 |
|
| New observations on the secondary chemistry of world Ephedra (Ephedraceae). | 2001-07 |
|
| Reappearance of cardiac presynaptic sympathetic nerve terminals in the transplanted heart: correlation between PET using (11)C-hydroxyephedrine and invasively measured norepinephrine release. | 2001-07 |
|
| Determination of ephedrine-type alkaloids in dietary supplements by LC/MS using a stable-isotope labeled internal standard. | 2001-06-22 |
|
| Perioperative bradycardia and asystole: relationship to vasovagal syncope and the Bezold-Jarisch reflex. | 2001-06 |
|
| Spinal anaesthesia for Caesarean section with bupivacaine 5 mg ml(-1) in glucose 8 or 80 mg ml(-1). | 2001-06 |
|
| Hypotension in spinal anesthesia for cesarean section: a comparison of 0.5% hyperbaric bupivacaine and 5% hyperbaric lidocaine. | 2001-06 |
|
| Cold-syrup induced movement disorder. | 2001-06 |
|
| It's a rave new world: rave culture and illicit drug use in the young. | 2001-06 |
|
| Nutritional supplements as a source for positive doping cases? | 2001-06 |
|
| Extra-strong graduated compression stocking reduces usage of vasopressor agents during spinal anesthesia for cesarean section. | 2001-05 |
|
| Stimulatory effect of D-ephedrine on beta3-adrenoceptors in adipose tissue of rats. | 2001-04-12 |
|
| Recurrent ischaemic colitis associated with pseudoephedrine use. | 2001-04 |
|
| Evaluation of pre-emptive intramuscular phenylephrine and ephedrine for reduction of spinal anaesthesia-induced hypotension during Caesarean section. | 2001-03 |
|
| Comparison of effects of remifentanil and alfentanil on cardiovascular response to tracheal intubation in hypertensive patients. | 2001-01 |
|
| Caffeine and exercise: metabolism, endurance and performance. | 2001 |
|
| Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats. | 2001 |
|
| Prevention of generalized reactions to contrast media: a consensus report and guidelines. | 2001 |
|
| A history of nebulization. | 2001 |
|
| New imaging techniques for cardiovascular autonomic neuropathy: a window on the heart. | 2001 |
Sample Use Guides
The recommended dosages for the treatment of clinically important hypotension in the setting of
anesthesia is an initial dose of 5 to 10 mg administered by intravenous bolus. Administer additional boluses as needed, not to exceed a total dosage of 50 mg.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6111369
Segments of guinea-pig ileum were treated with 10(-6)-10(-3) M ephedrine. Ephedrine inhibited the ileal responses to transmural stimulation in the terminal and the proximal ileum with EC50 values of 57.2 and 85.5 uM, respectively. In the proximal part of the ileum, more than 70% of preparations were relaxed by ephedrine.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:45:16 GMT 2025
by
admin
on
Mon Mar 31 18:45:16 GMT 2025
|
| Record UNII |
GN83C131XS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
S01FB02
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
WHO-ATC |
R01AA03
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
WHO-VATC |
QC01CA26
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
WHO-ATC |
R03CA02
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
NDF-RT |
N0000175552
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
1.2
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
CFR |
21 CFR 119.1
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
WHO-VATC |
QR01AA03
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
CFR |
21 CFR 1315.13
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
WHO-ATC |
C01CA26
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
WHO-VATC |
QS01FB02
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
CFR |
21 CFR 341.20
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
NCI_THESAURUS |
C87053
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
NDF-RT |
N0000175555
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
WHO-VATC |
QG04BX90
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
NDF-RT |
N0000192563
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
DEA NO. |
8113
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
CFR |
21 CFR 341.16
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
WHO-ATC |
A08AA56
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
CFR |
21 CFR 1314.20
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
WHO-VATC |
QR03CA02
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
WHO-ATC |
R01AB05
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
||
|
WHO-VATC |
QR01AB05
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
170951
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
SUB13683MIG
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
DB01364
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
1024
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
100000088883
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
3072
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
D004809
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
206-080-5
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
9294
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
EPHEDRINE
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
8971
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
SUB11936MIG
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
GN83C131XS
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
C472
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
m4933
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
299-42-3
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
EPHEDRINE
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | Description: Colourless crystals or a white, crystalline powder; odourless or with a slight, aromatic odour.Solubility: Soluble in water; very soluble in ethanol (~750 g/l) TS; freely soluble in ether R.Category: Antiasthmatic drug.Storage: Ephedrine should be kept in a well-closed container, protected from light.Labelling: The designation on the container should state whether the substance is the hemihydrate or is in the anhydrous form.Additional information. Solutions of Ephedrine in chloroform R may become turbid, especially when the substance contains morethan 10 mg of water per g. Even in the absence of light, Ephedrine is gradually degraded on exposure to a humid atmosphere,the decomposition being faster at higher temperatures. Anhydrous Ephedrine melts at about 38?C, whereas Ephedrinehemihydrate melts at about 42?C. | ||
|
GN83C131XS
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
3966
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | RxNorm | ||
|
556
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
DTXSID0022985
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
CHEMBL211456
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY | |||
|
15407
Created by
admin on Mon Mar 31 18:45:16 GMT 2025 , Edited by admin on Mon Mar 31 18:45:16 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
PARENT->PRECURSOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
SOLVATE->ANHYDROUS |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT->PRECURSOR |
|
||
|
SALT/SOLVATE -> PARENT |
Definition. Ephedrine contains not less than 98.5% and not more than 101.0% of C10H15NO, calculated with reference to the anhydrous substance.
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|